Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis

Journal of Hepatology

Volumn 63, Issue 5, 2015, Pages 1190-1197

  Hsiang, John Chen ^a   Wong, Grace Lai Hung ^a   Tse, Yee Kit ^a   Wong, Vincent Wai Sun ^a   Yip, Terry Cheuk Fung ^a   Chan, Henry Lik Yuen ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Alanine aminotransferase; Albumin; Death; Hepatitis B; Hepatocellular carcinoma; Landmark analysis; Nucleos(t)ide analogue.; Statin

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CHRONIC HEPATITIS B; COHORT ANALYSIS; DRUG EFFECT; FEMALE; FOLLOW UP; HONG KONG; HOSPITAL INFECTION; HUMAN; ICD-9; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; RISK REDUCTION; SENSITIVITY ANALYSIS; AGED; CARCINOMA, HEPATOCELLULAR; CAUSE OF DEATH; CLINICAL TRIAL; COMPLICATION; CROSS INFECTION; HEPATITIS B, CHRONIC; HOSPITAL PATIENT; INCIDENCE; LIVER NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL RATE; TRENDS;

AGED; CARCINOMA, HEPATOCELLULAR; CAUSE OF DEATH; CROSS INFECTION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B, CHRONIC; HONG KONG; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; INPATIENTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROPENSITY SCORE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84945445250     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.07.009     Document Type: Article

References (42)

1. J.M. Llovet, A. Burroughs, and J. Bruix Hepatocellular carcinoma Lancet 362 2003 1907 1917
2. G.V. Papatheodoridis, P. Lampertico, S. Manolakopoulos, and A. Lok Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review J Hepatol 53 2010 348 356
3. G.L. Wong, H.L. Chan, C.W. Mak, S.K. Lee, Z.M. Ip, A.T. Lam, and et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis Hepatology 58 2013 1537 1547
4. N. Chalasani, H. Aljadhey, J. Kesterson, M.D. Murray, and S.D. Hall Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity Gastroenterology 126 2004 1287 1292
5. S. Khorashadi, N.K. Hasson, and R.C. Cheung Incidence of statin hepatotoxicity in patients with hepatitis C Clin Gastroenterol Hepatol 4 2006 902 907 Quiz 806
6. J.H. Lewis, M.E. Mortensen, S. Zweig, M.J. Fusco, J.R. Medoff, R. Belder, and et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial Hepatology 46 2007 1453 1463
7. C. Motzkus-Feagans, A.L. Pakyz, S.M. Ratliff, J.S. Bajaj, and K.L. Lapane Statin use and infections in Veterans with cirrhosis Aliment Pharmacol Ther 38 2013 611 618
8. S. Singh, P.P. Singh, A.G. Singh, M.H. Murad, and W. Sanchez Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis Gastroenterology 144 2013 323 332
9. A. Lonardo, and P. Loria Potential for statins in the chemoprevention and management of hepatocellular carcinoma J Gastroenterol Hepatol 27 2012 1654 1664
10. Z. Cao, H. Fan-Minogue, D.I. Bellovin, A. Yevtodiyenko, J. Arzeno, Q. Yang, and et al. MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase Cancer Res 71 2011 2286 2297
11. Y.T. Tsan, C.H. Lee, J.D. Wang, and P.C. Chen Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection J Clin Oncol 30 2012 623 630
12. S. Singh, P.P. Singh, L.R. Roberts, and W. Sanchez Chemopreventive strategies in hepatocellular carcinoma Nat Rev Gastroenterol Hepatol 11 2014 45 54
13. A. Giobbie-Hurder, R.D. Gelber, and M.M. Regan Challenges of guarantee-time bias J Clin Oncol 31 2013 2963 2969
14. F. Carrat Statin and aspirin for prevention of hepatocellular carcinoma: what are the levels of evidence? Clin Res Hepatol Gastroenterol 38 2014 9 11
15. J. Fung, C.L. Lai, M.F. Yuen, and I.O. Ng Do statins reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis B? Hepatobiliary Sci Nutr 2 2013 34 36
16. L.E. Levesque, J.A. Hanley, A. Kezouh, and S. Suissa Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes BMJ 340 2010 b5087
17. U. Dafni Landmark analysis at the 25-year landmark point Circ Cardiovasc Qual Outcomes 4 2011 363 371
18. J.R. Anderson, K.C. Cain, and R.D. Gelber Analysis of survival by tumor response J Clin Oncol 1 1983 710 719
19. J. Chubak, D.M. Boudreau, H.S. Wirtz, B. McKnight, and N.S. Weiss Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival J Natl Cancer Inst 105 2013 1456 1462
20. Y.F. Liaw, N. Leung, J.H. Kao, T. Piratvisuth, E. Gane, K.H. Han, and et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update Hepatol Int 2 2008 263 283
21. WHO Collaborating centre for drug statistics methodology, guidelines for ATC classification and DDD assignment, 2015. Oslo. 2014. [cited; Available from: < http://www.whocc.no/filearchive/publications/2015-guidelines.pdf >.
22. M.M. Hassan, S.A. Curley, D. Li, A. Kaseb, M. Davila, E.K. Abdalla, and et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma Cancer 116 2010 1938 1946
23. S. Singh, P.P. Singh, A.G. Singh, M.H. Murad, and W. Sanchez Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis Am J Gastroenterol 108 2013 881 891 Quiz 892
24. H.P. Chen, J.J. Shieh, C.C. Chang, T.T. Chen, J.T. Lin, M.S. Wu, and et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies Gut 62 2013 606 615
25. L.E. Braitman, and P.R. Rosenbaum Rare outcomes, common treatments: analytic strategies using propensity scores Ann Intern Med 137 2002 693 695
26. D.F. McCaffrey, B.A. Griffin, D. Almirall, M.E. Slaughter, R. Ramchand, and L.F. Burgette A tutorial on propensity score estimation for multiple treatments using generalized boosted models Stat Med 32 2013 3388 3414
27. M. Pintilie Competing risks: a practical perspective 2006 John Wiley New York, NY
28. E.J. Mills, B. Rachlis, P. Wu, P.J. Devereaux, P. Arora, and D. Perri Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients J Am Coll Cardiol 52 2008 1769 1781
29. H.L. Chan, C.H. Tse, F. Mo, J. Koh, V.W. Wong, G.L. Wong, and et al. High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma J Clin Oncol 26 2008 177 182
30. V.W. Wong, S.L. Chan, F. Mo, T.C. Chan, H.H. Loong, G.L. Wong, and et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers J Clin Oncol 28 2010 1660 1665
31. C.Y. Wu, J.T. Lin, H.J. Ho, C.W. Su, T.Y. Lee, S.Y. Wang, and et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study Gastroenterology 147 2014 e145
32. A.P. Sutter, K. Maaser, M. Hopfner, A. Huether, D. Schuppan, and H. Scherubl Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor J Hepatol 43 2005 808 816
33. C. Arnaud, F. Burger, S. Steffens, N.R. Veillard, T.H. Nguyen, D. Trono, and et al. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins Arterioscler Thromb Vasc Biol 25 2005 1231 1236
34. T. Bader, and B. Korba Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro Antiviral Res 86 2010 241 245
35. Z. Younoszai, Z. Li, M. Stepanova, M. Erario, R. Cable, and Z.M. Younossi Statin use is not associated with liver related mortality Ann Hepatol 13 2013 84 90
36. K.K. Ray, S.R. Seshasai, S. Erqou, P. Sever, J.W. Jukema, I. Ford, and et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants Arch Intern Med 170 2010 1024 1031
37. H. Naci, J.J. Brugts, R. Fleurence, B. Tsoi, H. Toor, and A.E. Ades Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials Eur J Prev Cardiol 20 2013 641 657
38. J.C. Hsiang, E.J. Gane, W.W. Bai, and S.J. Gerred Type 2 diabetes: a risk factor for liver mortality and complications in hepatitis B cirrhosis patients J Gastroenterol Hepatol 30 2015 591 599
39. G. D'Amico, G. Garcia-Tsao, and L. Pagliaro Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies J Hepatol 44 2006 217 231
40. P.S. Kamath, R.H. Wiesner, M. Malinchoc, W. Kremers, T.M. Therneau, C.L. Kosberg, and et al. A model to predict survival in patients with end-stage liver disease Hepatology 33 2001 464 470
41. J.L. Lund, and J. Montomoli Common flaws in pharmacoepidemiologic study design and analysis J Clin Oncol 31 2013 4161 4162
42. L. McCleary Using multiple imputation for analysis of incomplete data in clinical research Nurs Res 51 2002 339 343